BlogNovember 1, 2023 Christi Myers Believes in the Power of Dissociative Therapy – Podcast Episode #37
PressNovember 1, 2023 Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
PressOctober 26, 2023 Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
PressOctober 26, 2023 Safe Supply Streaming Co. Ltd. Announces Appointment of Ronan Levy as President
PressOctober 25, 2023 ATMA Welcomes Dr. Scott Shannon, MAPS MDMA Phase 3 Principal Investigator, to Expand Its’ Clinical Training Expertise in MDMA-Assisted Therapy
PressOctober 25, 2023 First Patient Dosed in Beckley Psytech’s International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD)
PressOctober 25, 2023 The Healing Company’s Chopra and Swan Hellenic Announce Exclusive, Multi-Year Partnership With Launch of Well-Being Travel Experience “Explore & Restore”
PressOctober 25, 2023 Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
PressOctober 23, 2023 FSD Pharma Inc. Announces Filing in Connection with Proposed Arrangement with Celly Nu
PressOctober 23, 2023 Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
BlogOctober 20, 2023 Brain & Behavior Research Foundation Awards $10.2 Million in Young Investigator Grants to 150 Mental Health Scientists
Psychedelic NewsOctober 20, 2023 Roland Griffiths: An Extraordinary Life & Legacy in Psychedelic Research
PressOctober 19, 2023 Red Light Holland’s Fully Owned Subsidiary, Radix Motion, Granted Patent for 3D Movement Data and AI Innovations
PressOctober 19, 2023 Pioneers and Innovators in Psilocybin Treatments and How Big Pharma wants in on the Psychedelic Sector
